Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced the continuation of its ambitious 2024 share repurchase program, now initiating an additional buyback of up to DKK 3.14 billion.

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed share transactions by its board members and executives, highlighting a significant purchase of 1,400 American Depositary Receipts ...

even their letter O sometimes comes slashed in half. But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk…. a pharmaceutical firm with a market cap of a half ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and weight-loss markets. Hims & Hers anticipates selling a generic version of ...